LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Matthew Lindon has been appointed Chief Scientific Officer (CSO) of LIDDS AB. Matthew Lindon has over 20 years experience of drug discovery and development from the pharmaceutical sector and will assume his new role on March 1, 2022.
“I am very pleased to welcome Matthew to the company. LIDDS is still in a growth and expansion momentum and Matthew is an excellent complement to our team. I am confident that Matthew will contribute very positively to the continued development of LIDDS project portfolio with his strong experience from pre-clinical and clinical work” said Nina Herne, CEO of LIDDS. “We continue building our organization and the addition of Matthew is an important step in this work."
Matthew has a strong background from the pharmaceutical sector where he has been working as Senior Director and Global Project Leader with a focus on drug discovery and early clinical development at GSK, and most recently at AstraZeneca. He has a Bachelor of Science in Chemistry from the University of Leicester.
"I am delighted to have been appointed as CSO for LIDDS. The company is in an exciting phase, and I am very much looking forward to joining the team, and working with the ongoing projects. I find both them and the NanoZolid technology very promising”, commented Matthew Lindon.
For more information, please contact:
Nina Herne, CEO, Phone: +46 (0)70-714 74 57, Email: nina.herne@liddspharma.com
The information was submitted for publication, through the agency of the aforementioned contact person, on December 20, 2021 at 15.00 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Pharming Group announces the placement of €100 million convertible bonds due 202918.4.2024 15:04:30 CEST | Press release
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the "Shares"). The offer was fully subscribed. The New Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, Canada, Japan and South Africa. The New Bonds will have a principal amount of €100,000 each. The New Bonds will be issued at par and will carry a coupon of 4.50% per annum payable semi-annually in arrear in equal instalments on 25th April and 25th October of each y
Modelo Spiked Aguas Frescas Teams Up With Actress Francia Raisa and Community Changemaker Juixxe to Honor the Street Vendor Community18.4.2024 15:01:00 CEST | Press release
As Modelo Spiked Aguas Frescas expands to multiple markets, it celebrates street vendors who inspired the beverage by rewarding an aguas frescas street vendor with a custom-made cart and financial support to help grow their business CHICAGO, April 18, 2024 (GLOBE NEWSWIRE) -- Following a successful Las Vegas test launch, where Modelo Spiked Aguas Frescas was the #1 new Flavored Malt Beverage multipack and single serve*, Modelo is celebrating the expansion of Modelo Spiked Aguas Frescas to strong Modelo markets across the country by once again honoring the street vendor community that made traditional aguas frescas a beloved cultural staple. Partnering with actress Francia Raisa and Juixxe, a changemaker famous for uplifting the street vendor community, Modelo surprised the owner of Oxnard, CA-based Las Aguas 805, Salvador Gutierrez, with a new, custom-built street cart and a $5,000 cash gift to help him fuel the fiesta in his community with delicious aguas frescas for years to come. “A
Fluence Releases Annual Sustainability Report18.4.2024 15:00:00 CEST | Press release
Report outlines increased sustainability disclosures, including Fluence’s first Task Force on Climate-Related Financial Disclosures (TCFD) report ARLINGTON, Va., April 18, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a leading global provider of energy storage products and services, and optimization software for renewables and storage, issued its 2023 Sustainability Report (the “Report”) providing updates on the company’s sustainability strategy during the fiscal year ended September 30, 2023. The Report enhances and builds upon the sustainability disclosures from our inaugural sustainability report published in April 2023 and provides updates on Fluence’s sustainability strategy, including additional goals for 2024 and beyond. “Fluence operates with sustainability principles at our core and the urgency to address climate change imparts an urgency to our work. The speed at which we are moving towards our sustainability program commitments is a testament to
Decisions of Rapala VMC Corporation’s Annual General Meeting and Organising Meeting of the Board of Directors18.4.2024 15:00:00 CEST | Press release
RAPALA VMC CORPORATION, Decisions of general meeting, April 18, 2023 at 4:00 p.m. EET The Annual General Meeting (AGM) of Rapala VMC Corporation has on 18 April 2024 adopted the financial statement of the financial year 2023 and discharged the members of the Board of Directors and the CEO from liability for the financial year that ended on 31 December 2023. The AGM approved the remuneration report for governing bodies for the financial year 2023 and the remuneration policy for 2024-2027. The AGM approved the Board of Director’s proposal, according to which no dividend be paid based on the adopted balance sheet for the financial year 2023. The AGM approved that the Board of Directors consists of six members. Emmanuel Viellard, Julia Aubertin, Vesa Luhtanen and Alexander Rosenlew were re-elected as members of the Board of Directors and Pascal Lebard and Johan Berg were elected as new members. The AGM resolved that the annual fee paid to each Board member is EUR 25,000 and EUR 70,000 to t
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care18.4.2024 14:45:00 CEST | Press release
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies. Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers. Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's